No registrations found.
ID
Source
Brief title
Health condition
The age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population
Sponsors and support
Intervention
Outcome measures
Primary outcome
The age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population.
Secondary outcome
The age-specific seroprevalence against other infectious diseases, in particular those that might be vaccine-preventable in the near future and against those diseases with a frequent subclinical course.
By collecting additional samples, the relationship between immune status and carriage of potential pathogens, lifestyle factors and environmental factors can be studied.
Background summary
Measuring the serological effects of the different vaccinations (immune surveillance) is an important tool for the evaluation of the National Immunisation Programme (NIP) by providing insight in the immune status of the population, by identifying possible gaps in the immunity and subpopulations at risk and by assessing (re) emergence of disease. To obtain insight into the age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population, this observational study with a single invasive measurement (drawing of blood) and non-invasive measurement (saliva) is performed. For a subgroup, optional, a nose and throat swab will be collected as well as a faecal sample. A representative part sample of the Dutch population (age 0-89 years) is invited to participate. The age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population and against other infectious diseases, in particular those that
might be vaccine-preventable in the near future and against those diseases with a frequent
subclinical course, will be asessed.
Study objective
Rationale: Measuring the serological effects of the different vaccinations (immune surveillance) is an important tool for the evaluation of the National Immunisation Programme (NIP) by providing insight in the immune status of the population, by identifying possible gaps in the immunity and subpopulations at risk and by assessing (re) emergence of disease.
Study design
A single time point for the collection of samples.
Intervention
None
R.A.J. Boxtel, van
Bilthoven 3721 MA
The Netherlands
+31 (0)30 2742755
renee.van.boxtel@rivm.nl
R.A.J. Boxtel, van
Bilthoven 3721 MA
The Netherlands
+31 (0)30 2742755
renee.van.boxtel@rivm.nl
Inclusion criteria
• Subject is part of the national study sample drawn from the population register, aged 0 to 89 year old and has received a personal invitation for the PIENTER study.
• Subject has given written Informed Consent (IC) before the start of the study visit.
Exclusion criteria
None
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL5467 |
| NTR-old | NTR5611 |
| Other | NL54228.094.15 : IIV-284 |
Summary results
Mollema L, de Melker HE, Hahné SJM, van Weert JWM, Berbers GAM, van der Klis FRM. PIENTER 2 project: second research project on the protection against infectious diseases offered by the national immunization programme in the Netherlands. RIVM report 230421001/2009.<br>
PIENTER2 study 2006-2007: A summary of the main findings. Van der Klis FRM, Mollema L, van Weert JWM. RIVM report, April 2012.